Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.36)
# 344
Out of 5,149 analysts
232
Total ratings
50.35%
Success rate
19.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $225 → $226 | $186.67 | +21.07% | 13 | Feb 25, 2026 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $90 → $92 | $64.39 | +42.88% | 14 | Feb 23, 2026 | |
| CTNM Contineum Therapeutics | Downgrades: Equal-Weight | $23 → $14 | $14.10 | -0.71% | 5 | Jan 8, 2026 | |
| NBIX Neurocrine Biosciences | Downgrades: Equal-Weight | $173 → $175 | $131.14 | +33.45% | 32 | Jan 8, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $77 → $80 | $40.12 | +99.40% | 4 | Jan 6, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $60.72 | +16.93% | 14 | Dec 23, 2025 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $20.46 | -41.35% | 3 | Dec 8, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $9.66 | +96.69% | 5 | Nov 12, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $89.56 | +44.04% | 14 | Oct 16, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $60.55 | +30.47% | 5 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $28 | $15.73 | +78.00% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $14.10 | -85.82% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $5.50 | +136.36% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $14.34 | +653.14% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $22.07 | +149.21% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $22.50 | +6.67% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $64.36 | +32.07% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $26.20 | +3.05% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $4.01 | +772.82% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $2.63 | +52.09% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.62 | +146.91% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $4.95 | +182.83% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $4.05 | +23.46% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.91 | +3.09% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.16 | +762.07% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $40.74 | -46.00% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $10.67 | +1,291.75% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.85 | +6,967.14% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.07 | +47.42% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $12.04 | +5,282.06% | 6 | May 8, 2020 |
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $225 → $226
Current: $186.67
Upside: +21.07%
PTC Therapeutics
Feb 23, 2026
Maintains: Overweight
Price Target: $90 → $92
Current: $64.39
Upside: +42.88%
Contineum Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $14
Current: $14.10
Upside: -0.71%
Neurocrine Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $173 → $175
Current: $131.14
Upside: +33.45%
Crinetics Pharmaceuticals
Jan 6, 2026
Maintains: Overweight
Price Target: $77 → $80
Current: $40.12
Upside: +99.40%
Cytokinetics
Dec 23, 2025
Maintains: Overweight
Price Target: $65 → $71
Current: $60.72
Upside: +16.93%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $20.46
Upside: -41.35%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $9.66
Upside: +96.69%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $89.56
Upside: +44.04%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $60.55
Upside: +30.47%
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $15.73
Upside: +78.00%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $14.10
Upside: -85.82%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $5.50
Upside: +136.36%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $14.34
Upside: +653.14%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $22.07
Upside: +149.21%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.50
Upside: +6.67%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $64.36
Upside: +32.07%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $26.20
Upside: +3.05%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $4.01
Upside: +772.82%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $2.63
Upside: +52.09%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.62
Upside: +146.91%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $4.95
Upside: +182.83%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $4.05
Upside: +23.46%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.91
Upside: +3.09%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.16
Upside: +762.07%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $40.74
Upside: -46.00%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $10.67
Upside: +1,291.75%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.85
Upside: +6,967.14%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.07
Upside: +47.42%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $12.04
Upside: +5,282.06%